US2015158825A1PendingUtilityA1

Method for treating liver diseases of various origins

Assignee: TETS VIKTOR VENIAMINOVICHPriority: Jul 7, 2009Filed: Feb 2, 2015Published: Jun 11, 2015
Est. expiryJul 7, 2029(~3 yrs left)· nominal 20-yr term from priority
A61P 1/16C07D 239/66A61K 31/515
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to medicine, in particular to gastroenterology, and lies in the field of treatment of liver diseases of various origins. For this purpose, the hepatoprotective agent that is introduced to the patient is embodied as derivatives of bis(2-thio-4,6-dioxo-1,2,3,4,5,6-hexahydropyrimidine-5-yl) arylmethanes. The method provides reduction of the manifestations of cytolysis under the influence of damaging agents and a statistically significant reduction of dysproteinemia, it accelerates restoration of detoxifying processes of the liver, increases induction of endogenic interferon alfa and, consequently, makes the protection of liver cells during hepatitides of various origins more effective.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . A compound having formula: 
       
         
           
           
               
               
           
         
       
     
     
         3 . A method of reducing liver damage in a subject in need thereof comprising administering to said subject a therapeutically effective amount of the compound of  claim 2 . 
     
     
         4 . The method of  claim 3 , wherein the liver damage is caused by a chemical agent. 
     
     
         5 . The method of  claim 3 , wherein the liver damage is caused by a bacterial infection. 
     
     
         6 . The method of  claim 3 , wherein the liver damage is caused by radiation. 
     
     
         7 . The method of  claim 3 , wherein the liver damage is caused by a viral infection.

Join the waitlist — get patent alerts

Track US2015158825A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.